» Articles » PMID: 15607400

Sympathetic Dysfunction in Type 1 Diabetes: Association with Impaired Myocardial Blood Flow Reserve and Diastolic Dysfunction

Overview
Date 2004 Dec 21
PMID 15607400
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: This study was designed to explore the relationships of early diabetic microangiopathy to alterations of cardiac sympathetic tone and myocardial blood flow (MBF) regulation in subjects with stable type 1 diabetes.

Background: In diabetes, augmented cardiac sympathetic tone and abnormal MBF regulation may predispose to myocardial injury and enhanced cardiac risk.

Methods: Subject groups comprised healthy controls (C) (n = 10), healthy diabetic subjects (DC) (n = 12), and diabetic subjects with very early diabetic microangiopathy (DMA+) (n = 16). [(11)C]meta-hydroxyephedrine ([(11)C]HED) and positron emission tomography (PET) were used to explore left ventricular (LV) sympathetic integrity and [(13)N]ammonia-PET to assess MBF regulation in response to cold pressor testing (CPT) and adenosine infusion.

Results: Deficits of LV [(11)C]HED retention were extensive and global in the DMA+ subjects (36 +/- 31% vs. 1 +/- 1% in DC subjects; p < 0.01) despite preserved autonomic reflex tests. On CPT, plasma norepinephrine excursions were two-fold greater than in C and DC subjects (p < 0.05), and basal LV blood flow decreased (-12%, p < 0.05) in DMA+ but not in C or DC subjects (+45% and +51%, respectively). On adenosine infusion, compared with C subjects, MBF reserve decreased by approximately 45% (p < 0.05) in DMA+ subjects. Diastolic dysfunction was detected by two-dimensional echocardiography in 5 of 8 and 0 of 8 consecutively tested DMA+ and DC subjects, respectively.

Conclusions: Augmented cardiac sympathetic tone and responsiveness and impaired myocardial perfusion may contribute to myocardial injury in diabetes.

Citing Articles

Insulin-Heart Axis: Bridging Physiology to Insulin Resistance.

Caturano A, Galiero R, Vetrano E, Sardu C, Rinaldi L, Russo V Int J Mol Sci. 2024; 25(15).

PMID: 39125938 PMC: 11313400. DOI: 10.3390/ijms25158369.


The double burden: type 1 diabetes and heart failure-a comprehensive review.

Julian M, Perez-Montes de Oca A, Julve J, Alonso N Cardiovasc Diabetol. 2024; 23(1):65.

PMID: 38347569 PMC: 10863220. DOI: 10.1186/s12933-024-02136-y.


Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease.

Dai Z, Chen J, Zou R, Liang X, Tang J, Yao C Front Immunol. 2023; 14:1213473.

PMID: 37809091 PMC: 10552262. DOI: 10.3389/fimmu.2023.1213473.


Cardiovascular Autonomic Neuropathy and Risk of Kidney Function Decline in Type 1 and Type 2 Diabetes: Findings From the PERL and ACCORD Cohorts.

Tang Y, Ang L, Jaiswal M, Dillon B, Esfandiari N, Shah H Diabetes. 2023; 73(5):751-762.

PMID: 37467433 PMC: 11043059. DOI: 10.2337/db23-0247.


Treatment of HFpEF beyond the SGLT2-Is: Does the Addition of GLP-1 RA Improve Cardiometabolic Risk and Outcomes in Diabetic Patients?.

Belli M, Barone L, Bellia A, Sergi D, Lecis D, Prandi F Int J Mol Sci. 2022; 23(23).

PMID: 36498924 PMC: 9737325. DOI: 10.3390/ijms232314598.